secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001493152-24-042677
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma completes enrollment agreements for Phase 2 Ropidoxuridine glioblastoma trial
--------------------------------------------------------------------------------

- All six trial sites finalized: Georgetown, UNC, UVA, Hackensack, Allegheny Health Network, Miami Cancer Institute.
- Patient screening underway; 40 patients randomized to 1,200 mg/day or 960 mg/day dose groups.
- Optimal dose group will add 14 patients for survival comparison vs historical controls; trial completion in 18-24 months.
- Ropidoxuridine holds FDA Orphan Drug Designation for glioblastoma, offering potential marketing exclusivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224042677/0001493152-24-042677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224042677/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer